UK Markets closed

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.53-0.35 (-4.44%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5257.67M
Enterprise value 3192.4M
Trailing P/E N/A
Forward P/E 1-3.64
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)7.50
Price/book (mrq)N/A
Enterprise value/revenue 35.60
Enterprise value/EBITDA 7-4.72

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 358.37
52-week low 37.34
50-day moving average 39.29
200-day moving average 322.40

Share statistics

Avg vol (3-month) 3527.05k
Avg vol (10-day) 3208.54k
Shares outstanding 534.22M
Implied shares outstanding 6N/A
Float 29.78M
% held by insiders 112.31%
% held by institutions 160.44%
Shares short (14 Jun 2021) 45.98M
Short ratio (14 Jun 2021) 414
Short % of float (14 Jun 2021) 424.37%
Short % of shares outstanding (14 Jun 2021) 417.47%
Shares short (prior month 13 May 2021) 45.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021


Profit margin -122.12%
Operating margin (ttm)-122.47%

Management effectiveness

Return on assets (ttm)-11.51%
Return on equity (ttm)-24.53%

Income statement

Revenue (ttm)34.37M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)-36.00%
Gross profit (ttm)36.98M
EBITDA -40.78M
Net income avi to common (ttm)-41.97M
Diluted EPS (ttm)-10.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)194.91M
Total cash per share (mrq)5.7
Total debt (mrq)46.48M
Total debt/equity (mrq)26.20
Current ratio (mrq)10.58
Book value per share (mrq)-25.04

Cash flow statement

Operating cash flow (ttm)-61.3M
Levered free cash flow (ttm)-46.61M